Effect of interferon-alpha-based antiviral therapy on hepatitis C virus-associated glomerulonephritis: A meta-analysis

Nephrology Dialysis Transplantation

Volumn 27, Issue 2, 2012, Pages 640-646

  Feng, Bo ^a   Eknoyan, Garabed ^b   Guo, Zhong Sheng ^a   Jadoul, Michel ^c   Rao, Hui Ying ^a   Zhang, Wei ^a   Wei, Lai ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

chronic kidney disease; hepatitis C; interferon; meta analysis

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; CREATININE; LYMPHOBLAST INTERFERON; PEGINTERFERON ALPHA; PROTEIN; RIBAVIRIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); CONFIDENCE INTERVAL; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; FEMALE; GLOMERULONEPHRITIS; HEPATITIS C VIRUS; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MICROBIOLOGICAL PARAMETERS; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RISK FACTOR; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; VIRAL CLEARANCE;

ANTIVIRAL AGENTS; COMORBIDITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84863115995     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr236     Document Type: Article

References (34)

1. Who Health Organization. Weekly Epidemiological Record. No. 49, 10 December 1999, WHO;
2. Hepatitis C fact sheet N0. 164, October 2000http://www.who.int/inf-fs/en/ fact164.html (September 2006, date last accessed)
3. Galossi A, Guarisco R, Bellis L et al. Extrahepatic manifestations of chronic HCV infection. J Gastrointesint Liver Dis 2007; 16: 65-73
4. Tsui JI, Vittinghoff E, Shlipak MG et al. Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. Arch Intern Med 2007; 167: 1271-1276
5. Crook ED, Penumalee S, Gavini B et al. Hepatitis C is a predictor of poorer renal survival in diabetic patients. Diabetes Care 2005; 28: 2187-2191
6. Sansonno D, Lauletta G, Montrone M et al. Hepatitis C virus RNA and core protein in kidney glomerular and tubular structures isolated with laser capture microdissection. Clin Exp Immunol 2005; 140: 498-506
7. Perico N, Cattaneo D, Bikbov B et al. Hepatitis C infection and chronic renal diseases. Clin J Am Soc Nephrol 2009; 4: 207-220
8. Alric L, Plaisier E, Thebault S et al. Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. Am J Kidney Dis 2004; 43: 617-623
9. Barsoum RS. Hepatitis C virus: from entry to renal injury-facts and potentials. Nephrol Dial Transplant 2007; 22: 1840-1848
10. Misiani R, Bellavita P, Fenili D et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994; 330: 751-756
11. Garini G, Allegri L, Iannuzzella F et al. HCV-related cryoglobulinemic glomerulonephritis: implications of antiviral and immunosuppressive therapies. Acta Biomed 2007; 78: 51-59
12. Johnson RJ, Gretch D, Yamabe H et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993; 328: 465-470
13. Sabry A, Sobh MA, Irving WL et al. A comprehensive study of the association between hepatitis C virus and glomerulopathy. Nephrol Dial Transplant 2002; 17: 239-245
14. Uchiyama-Tanaka Y, Mori Y, Kishimoto N et al. Membranous glomerulonephritis associated with hepatitis C virus infection: case report and literature review. Clin Nephrol 2004; 61: 144-150
15. Levey AS, Coresh J, Balk E et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137-147
16. GhanyMG, Strader DB, Thomas DL et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374
17. Fabrizi F, Lunghi G, Messa P et al. Therapy of hepatitis C virus-associated glomerulonephritis: current approaches. J Nephrol 2008; 21: 813-825
18. Garini G, Allegri L, Carnevali L et al. Interferon-alpha in combination with ribavirin as initial treatment for hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis. Am J Kidney Dis 2001; 38: E35
19. Loustaud-Ratti V, Liozon E, Karaaslan H et al. Interferon alpha and ribavirin for membranoproliferative glomerulonephritis and hepatitis C infection. Am J Med 2002; 113: 516-519
20. Rossi P, Bertani T, Baio P et al. Hepatitis C virus-related cryoglobulinemic glomerulonephritis: long-term remission after antiviral therapy. Kidney Int 2003; 63: 2236-2241
21. Boonyapisit K, Katirji B. Severe exacerbation of hepatitis C-associated vasculitic neuropathy following treatment with interferon alpha: a case report and literature review. Muscle Nerve 2002; 25: 909-913
22. Otha S, Yokoyama H, Wada T et al. Exacerbation of glomerulonephritis in subjects with chronic hepatitis C virus infection after interferon therapy. Am J Kidney Dis 1999; 33: 1040-1048
23. Yamabe H, Johnson RJ, Gretch DR et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection responsive to interferon-alpha. Am J Kidney Dis 1995; 25: 67-69
24. Mazzaro C, Panarello G, Carniello S et al. Interferon versus steroids in patients with hepatitis C virus-associated cryoglobulinaemic glomerulonephritis. Dig Liver Dis 2000; 32: 708-715
25. Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med 2002; 21: 1539-1558
26. Abbas G, Hussain S, Shafi T. Effect of antiviral therapy on hepatitis C virus related glomerulopathy. Saudi J Kidney Dis Transplant 2008; 19: 775-780
27. Beddhu S, Bastacky S, Johnson JP. The Clinical and Morphologic Spectrum of Renal Cryoglobulinemia. Medicine 2002; 81: 398-409
28. Bruchfeld A, Lindahl K, Stahle L et al. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant 2003; 18: 1573-1580
29. Johnson RJ, Gretch DR, Couser WG et al. Hepatitis C virus-associated glomerulonephritis. Effect of a-interferon therapy. Kidney Int 1994; 46: 1700-1704
30. Komatsuda A, Imai H, Wakui H et al. Clinicopathological analysis and therapy in hepatitis C virus-associated nephropathy. Intern Med 1996; 35: 529-533
31. Bruchfeld A, Lindahl K, Stahle L et al. Interferon/pegylated interferon and ribavirin in HCV-associated kidney disease with or without cryoglobulinemia. J Hepatol 2006; 44: 432-435
32. Diamond DA, Davis GL, Qian KP et al. Detection of hepatitis C viral sequences in formalin-fixed, paraffin-embedded liver tissue: effect of interferon Alpha therapy. J Med Virol 1994; 42: 294-298
33. Quigg RJ, Brathwaite M, Gardner DF et al. Successful cyclophosphamide treatment of cryoglobulinemic membranoproliferative glomerulonephritis associated with hepatitis C virus infection. Am J Kidney Dis 1995; 25: 798-800
34. Fabrizi F, Bruchfeld A, Mangano S et al. Interferon therapy for HCVassociated glomerulonephritis: meta-analysis of controlled trials. Int J Artif Organs 2007; 30: 212-219